AstraZeneca (AZN) Downgraded by Bank of America Merrill Lynch to "Neutral"
Friday, July 22, 2021 1:32 PM

Equities research analysts at Bank of America Merrill Lynch downgraded shares of AstraZeneca (NYSE: AZN) from a "buy" rating to a "neutral" rating in a research note to investors on Friday.

Separately, analysts at Jefferies downgraded shares of AstraZeneca from a "hold" rating to an "underperform" rating in a research note to investors on Thursday, June 2nd. Also, analysts at Collins Stewart upgraded shares of AstraZeneca to a "hold" rating in a research note to investors on Thursday, January 27th.

Shares of AstraZeneca traded down 1.56% during mid-day trading on Monday, hitting $49.69. AstraZeneca has a 52 week low of $44.98 and a 52 week high of $53.53. The stock's 50-day moving average is $50.06 and its 200-day moving average is $49.03. The company has a market cap of $68.771 billion and a price-to-earnings ratio of 8.83.

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines for six areas of healthcare. Its six areas of healthcare includes cardiovascular, gastrointestinal, infection, neuroscience, oncology, and respiratory and inflammation. The Company’s products include Crestor, Nexium, Synagis, Seroquel, Arimidex and Symbicort. The Company owns and operates a range of research and development (R&D), production and marketing facilities worldwide.

Stay on top of analysts' coverage with American Banking & Market News' daily email newsletter that provides a concise list of analysts' upgrades, analysts' downgrades and analysts' price target changes for each day.Click here to register.